WinstonWınston
Zimmer Biomet Holdings logo

Zimmer Biomet Holdings

ZBH
47
Medical - Devices · Healthcare
Price
$91.12
-2.63 (-2.81%)
Market Cap
$17.63B
Winston Score
47
Winston is serious
Mixed quality — meaningful strengths and weaknesses.

Share count falling — buybacks

5.6% over 4y

The company has reduced its share count over this period, returning value to shareholders through buybacks.

Diluted shares outstanding: 210.4M (2021) → 198.7M (2025)

Zimmer Biomet makes medical devices used to replace or repair damaged joints in the human body. Its main products are artificial knees, hips, shoulders, and spine implants, which are sold to hospitals and surgeons around the world. The company is one of the largest orthopedic device makers globally, competing closely with a small group of rivals including Stryker and Johnson & Johnson.

Zimmer Biomet earns money by selling its implants and related surgical instruments directly to hospitals and surgical centers. It operates in over 25 countries, with the United States generating the largest share of its roughly $7 billion in annual revenue. The company's moat comes from deep relationships with surgeons, who tend to stick with the implant systems they are trained on. The key growth driver is an aging global population that will need more joint replacements over time, while the main risk is ongoing pressure from hospital customers to lower device prices.

Winston Score History

Politician Trades

19 trades / 12mo

12 Congressional buys and 7 sells on ZBH in the last 12 months.

Unlock the full Smart Money Map — every trade plotted on the price chart with politicians, amounts and returns since each trade. Founder's Deal is $57/mo locked for life.

Unlock politician trades

Growth Profile

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

+9.3% YoY

YoY Growth Rate

Slow revenue growth

EPS Growth

+32.6% YoY

YoY Growth Rate

EPS growth accelerating

R&D Spend

$459M/ year

Flat (+5% vs prior year)

5.6% of revenue

Below sector average (18%)

Steady R&D investment year-over-year

Insider Activity

0.2%ownership

Flat

Insiders holding steady — not selling despite ability to

Cash Position

Cash flow positive

$424M cash & investments

Quarterly Free Cash Flow

↑ Burn rate improving

Company generates more cash than it spends — no dilution risk from fundraising

Growth context

Zimmer Biomet Holdings is growing revenue at 9% year-over-year. The Winston Score measures business quality today — these growth metrics show what could matter tomorrow.

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Gross Margin
72.4%
Premium pricing power — 72.4% gross margin
Operating Margin
17.9%
Healthy — 17.9% operating margin
ROCE
1.7%
Weak — 1.7% return on capital

ROIC between 0% and 5%. They earn a few cents back per dollar invested in the business.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales YoY
+9.2%
Steady sales growth (9.2% YoY)
EPS YoY
-14.6%
Earnings shrinking (-14.6% YoY)

Earnings per share down more than 10%. Either a bad year, or a real decline.

EPS Consistency
2/8 quarters
Earnings rarely grow — volatile business

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Cash Conversion
220%
Turns 220% of profit into real cash
FCF Margin
15.2%
Converts sales into free cash efficiently (15.2%)

FCF margin between 10% and 20%. Every $100 in sales becomes $10 to $20 in real cash.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

Debt / Equity
0.51
Conservative — low debt load (0.51)
Interest Cover
4.44x
Adequate interest coverage (4.4x)

Interest coverage between 3 and 8. Profits cover interest several times over.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

P/E Ratio (TTM)
23.5x
Growth-priced — P/E 23.5

P/E above the market average. People are paying up for expected growth.

P/E vs Forward
+14.8
GROWING
Earnings expected to grow meaningfully — cheaper on forward P/E (23.5 → 8.7)

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Dividend Yield
1.14%
Small dividend — 1.14% yield

Modest yield. The bulk of any return needs to come from price appreciation.

Dividend Growth
+0.0%
Dividend flat

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free
🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.
Start free trial